Document:

exhibit101-transitionand

EXHIBIT 10.1          January 15, 2021  Mr. Neil Parikh       Re: Transition and Release of Claims Agreement  Dear Neil:   This letter agreement (this “Letter Agreement”), entered into on the date first set forth  above (the “Effective Date”), sets forth the understanding by and between you and Casper Sleep  Inc. (collectively with its direct and indirect subsidiaries, and any successor(s) thereto, the  “Company”), regarding the cessation of your employment with the Company and the transition of  your role as Chief Strategy Officer of the Company to your successor.    1. Separation Date and Transition Services.    a. Your active employment with the Company will terminate on January 31,  2021 (the “Separation Date”) and, as of the Separation Date, you will cease to be an employee and  officer of the Company and its direct and indirect subsidiaries. Until the Separation Date you will  continue to perform your duties as Chief Strategy Officer of the Company, consistent with past  practices, unless otherwise requested by the Board of Directors of the Company (the “Board”),  and that certain At-Will Employment Agreement, Confidential Information, Invention Assignment  and Arbitration Agreement by and between the Company and you, dated as of July 9, 2014 (the  “Employment Agreement”) and the Executive Severance and Change in Control Agreement by  and between you and the Company, dated as of July 24, 2020 (the “Severance Agreement”) will  continue to control with respect to your salary, benefits and other matters with respect to your  employment with the Company; provided, that you agree that during the period beginning on the  Separation Date and ending on the earlier of (x) the date of termination of your services as a  director of the Company and its subsidiaries and (y) January 31, 2022 (the “Transition Period”),  you will continue to serve the Company for the duties described below as may be specified from  time to time by the Board. In particular, during the Transition Period you agree you will (i) provide  guidance with respect to the ongoing operations of the Company to the Board and/or executives  of the Company, (ii) continue to represent the Company in public relations and marketing  opportunities, (iii) assist with corporate development and brand and product partnership sourcing  and opportunities, and (iv) communicate a message consistent with the Board’s direction to key  employees, customers and suppliers. You acknowledge and agree that, effective at 12:01 a.m.,  Eastern time, on the Separation Date, you hereby resign as Chief Strategy Officer and as an  employee of the Company and from all offices and positions you may hold at the Company’s  subsidiaries; provided, that, following the Separation Date you will continue to serve as a member  of the Board and in any other directorships you may hold at the Company and its subsidiaries.  b. In connection with your services during the Transition Period, you shall  make yourself reasonably available (in person, by telephone or otherwise) to consult with the  Board and the Company’s executive officers. In addition, you shall make yourself available to  travel in connection with your services if reasonably requested by the Board and any reasonable  

 

EXHIBIT 10.1  2      travel expenses associated therewith shall be reimbursed in accordance with the Company’s  applicable policies. You shall report to the Board during the Transition Period. Except as set forth  in Section 2, you shall not be entitled to any fees or other compensation in exchange for your  services during the Transition Period.  The parties hereto acknowledge and agree that the Company  intends to require you to, and you intend to, perform services during the Transition Period at a  level equal to or less than 10% of your average level of service previously performed for the  Company during the 36-month period immediately preceding the Separation Date; provided that  in no event shall you be required to perform more than four (4) hours of services during any given  week without your consent, excluding any time you may spend on fulfilling your duties and  responsibilities as a director of the Board.  Your services described in Sections 1(a) and (b) are herein referred to, collectively, as the  “Transition Services.”    2. Severance Benefits.  In addition to any payments and benefits due to you pursuant  to Section 3(a) of the Severance Agreement, you will, subject to (and in consideration for) your  execution and non-revocation of the Waiver and Release of Claims Agreement attached hereto as  Exhibit A (the “Release”), be entitled to receive payments and benefits set forth in Section 3(b)(i)  of the Severance Agreement as if your employment was terminated by the Company without Cause  outside of the Change in Control Protection Period (each defined in the Severance Agreement)  (collectively, the “Severance Benefits”). The Severance Benefits shall be subject to the terms of  the Severance Agreement (including, without limitation, Section 12 of the Severance Agreement)  and, for the avoidance of doubt, will consist of (a) continued base salary for 12 months following  the Separation Date, which equals an aggregate amount of $325,000, (b) reimbursement during  the Continuation Period (as defined in the Severance Agreement) of the Company-paid portion of  premium payments, as if you had remained an active employee, for any COBRA coverage that  you timely elect, which shall be payable monthly, and (c) the annual bonus earned by you with  respect to 2020.    3.  Board Service.   (a) Following the Separation Date you will continue to serve as a member of  the Board unless and until your service terminates. In exchange for (and subject to) your continued  service as a director following the Separation Date, you will be eligible to receive compensation  pursuant to the Casper Sleep Inc. Non-Employee Director Compensation Policy (as in effect from  time to time, the “Director Compensation Policy”) commencing as of February 1, 2022; provided,  that, for the avoidance of doubt, you will not be entitled to an Initial Award (as defined in the  Director Compensation Policy) under the Director Compensation Policy. For the avoidance of  doubt, you hereby waive the right to receive any compensation pursuant to the Director  Compensation Policy during the Transition Period.  So long as you will continue to serve as a  Board member following the first annual meeting of the Company’s stockholders after  February  1, 2022, you shall be entitled to the annual grant of equity awarded to non-employee directors of  the Board commencing in 2022.  (b) Following the Separation Date, you will continue to be covered by the  Company’s directors and officers liability insurance during your service as a member of the Board.  

 

EXHIBIT 10.1  3      In addition, you will continue to be eligible for the Company’s annual product discount for so long  as you serve as a member of the Board.   (c) For the avoidance of doubt, the following unvested equity awards held by  you as of the Separation Date will remain outstanding and continue to vest so long as you continue  to serve a member of the Board: (i) 56,250 options in the Company, awarded to you on January 2,  2018 with an exercise price of $13.60 per share (the “2018 Options”); (ii) 120,000 options in the  Company, awarded to you on July 19, 2019 with an exercise price of $19.65 per share (“2019  Options” and together with the 2018 Options, the “Options”)); and (iii) 76,924 restricted stock  units, awarded to you on March 5, 2020. Notwithstanding the foregoing, if your service as a  member of the Board is terminated for any reason other than for Cause (as defined in the Casper  Sleep Inc. 2020 Equity Incentive Plan), your Options will accelerate and vest as to a pro rata  portion of such Options equal to the product of (1) the number of 2018 Options or 2019 Options,  as applicable, and (2) a fraction, (x) the numerator of which is the number of days elapsed between  the grant date and the date of termination of your service on the Board, and (y) the denominator of  which is the number of days between the grant date and the vesting date of such 2018 or 2019  Options, as applicable, as set forth in the applicable option agreement by and between you and the  Company (with any remaining unvested options being forfeited automatically for no  consideration), and your restricted stock units will accelerate in full (to the extent not previously  vested) as of such date of termination. In addition, the Company hereby amends the post- termination exercise period of your outstanding Options as well as the remaining vested 168,750  options in the Company awarded to you on January 2, 2018, through the date that is the later of  (1) the five-year anniversary of the Separation Date and (2) the 90th day following the termination  of your service on the Board  (such collective benefits as are set forth in this Section 3(c), the  “Additional Director Benefits”).     4. Restrictive Covenants.  You acknowledge that the Company is providing you with  the Additional Director Benefits in material part in consideration for your reaffirmation of your  prior agreement to comply with the restrictive covenants set forth in Sections 2 and 7 of the  Employment Agreement and that no accelerated vesting shall occur, following the date that you  have first violated any of Section 2, 7(a) or 7(b) of the Employment Agreement, as reasonably  determined by the Company.  5. Release.  The Severance Benefits are contingent upon and subject to your execution  and non-revocation of the Release following the Separation Date in accordance with Sections 3(c)  and 12(c) of the Severance Agreement, and you agree to sign and be bound by the Release which  will be considered an integral part of this Letter Agreement.   6.    Entire Agreement.  This Letter Agreement sets forth the entire agreement between  you and the Company with respect to the subject matter set forth herein and supersedes and  replaces any and all prior oral or written agreements or understandings between you and the  Company with respect to the subject matter hereof; provided, that, for the avoidance of doubt, (a)  you will retain your rights under the terms of the Employment Agreement and the Severance  Agreement, through the date on which all payments or benefits required to be provided thereunder  have been made or provided in their entirety, except to the extent such terms result in duplication  of compensation or benefits to you, and (b) the provisions of any indemnity agreement with the  Company and the Employment Agreement which by their terms survive termination of  

 

EXHIBIT 10.1  4      employment (including, without limitation, the restrictive covenants set forth in Sections 2 and 7  of the Employment Agreement, respectively) will remain in full force and effect in accordance  with their terms (as may be amended by this Letter Agreement).  This Letter Agreement may be  amended only by a subsequent writing signed by both parties. You represent that you have signed  this Letter Agreement knowingly and voluntarily.   [signature page follows]    

 

  Signature Page to Transition and Release of Claims Agreement    Please indicate your acceptance of the terms and provisions of this Letter  Agreement by signing both copies of this Letter Agreement and returning one copy to me.  The  other copy is for your files.  By signing below, you acknowledge and agree that you have carefully  read this Letter Agreement and Exhibit A thereto in their entirety; fully understand and agree to  their terms and provisions; will comply with the restrictive covenants set forth in Sections 2 and 7  of the Employment Agreement; and intend and agree that this Letter Agreement is final and legally  binding on you and the Company. All payments described in this Letter Agreement will be subject  to the withholding of any amounts required by federal, state or local law. This Letter Agreement  will be governed and construed under the internal laws of the State of New York and may be  executed in several counterparts.      Very truly yours,      /s/ Jonathan Truppman  Jonathan Truppman, General Counsel  On behalf of Casper Sleep Inc.          

 

  Signature Page to Transition and Release of Claims Agreement    Agreed, Acknowledged and Accepted as of the first date set forth above:      /s/ Neil Parikh  Neil Parikh        

 

       Exhibit A    Form of Release Agreement    This General Release of Claims (this “Release”) is made by Neil Parikh (“Employee”) in favor of  Casper Sleep Inc., a Delaware corporation (the “Company”) and the “Releasees” (as defined below), as of  the date of Employee’s execution of this Release.    1. Release by Employee. In exchange for the benefits set forth in the Transition and  Release of Claims Agreement entered into by and between the Company and Employee, dated as of January  15, 2021 (the “Agreement”), and for other good and valuable consideration, the receipt and adequacy of  which are hereby acknowledged, Employee agrees unconditionally and forever to release and discharge the  Company and the Company’s affiliated, related, parent and subsidiary corporations, as well as their  respective past and present parents, subsidiaries, affiliates, associates, members, stockholders, employee  benefit plans, attorneys, agents, representatives, partners, joint venturers, predecessors, successors, assigns,  insurers, owners, employees, officers, directors and all persons acting by, through, under, or in concert with  them, or any of them (hereinafter the “Releasees”) from any and all manner of claims, actions, causes of  action, in law or in equity, demands, rights, or damages of any kind or nature which he or she may now  have, or ever have, whether known or unknown, fixed or contingent, including any claims, causes of action  or demands of any nature (hereinafter called “Claims”), that Employee now has or may hereafter have  against the Releasees by reason of any and all acts, omissions, events or facts occurring or existing prior to  Employee’s execution of this Release. The Claims released hereunder specifically include, but are not  limited to, any claims for fraud; breach of contract; breach of implied covenant of good faith and fair  dealing; inducement of breach; interference with contract; wrongful or unlawful discharge or demotion;  violation of public policy; sexual or any other type of assault and battery; invasion of privacy; intentional  or negligent infliction of emotional distress; intentional or negligent misrepresentation; conspiracy; failure  to pay wages, benefits, vacation pay, severance pay, commissions, equity, attorneys’ fees, or other  compensation of any sort; failure to accommodate disability, including pregnancy; discrimination or  harassment on the basis of pregnancy, race, color, sex, gender, national origin, ancestry, religion, disability,  handicap, medical condition, marital status, sexual orientation or any other protected category; any claim  under the Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621 et seq. (“ADEA”); the  Older Workers’ Protection Benefit Act of 1990; Title VII of the Civil Rights Act of 1964, as amended, by  the Civil Rights Act of 1991, 42 U.S.C. § 2000 et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); the  Civil Rights Act of 1866, 42 U.S.C. § 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601  et seq.; the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq.; the False Claims Act, 31  U.S.C. § 3729 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et  seq.; the Worker Adjustment and Retraining Notification Act (“WARN”), as amended, 29 U.S.C. § 2101 et  seq.; the Fair Labor Standards Act, 29 U.S.C. § 215 et seq.; the New York Human Rights Law, N.Y. Exec  Law Art. 15, § 290 et seq.; the New York State WARN Act; the New York State Labor Law; the New York  City Human Rights Law; the New York City Earned Sick Time Act; Section 125 of the New York Workers’  Compensation Law, New York State Civil Rights Law, Article 23-A of the New York State Corrections  Law; and any federal, state or local laws of similar effect.     2. Claims Not Released.  This Release shall not apply to: the Company’s obligations to  provide the separation or director benefits under Section 2 of the Agreement; Sections 3(a) and 4 of the  Severance Agreement (as defined in the Agreement); Employee’s right to indemnification under any  applicable indemnification agreement with the Company; the Company’s governing documents or  applicable law; Employee’s right to assert claims for workers’ compensation or unemployment benefits;  Employee’s right to bring to the attention of the Equal Employment Opportunity Commission (“EEOC”)  

 

EXHIBIT 10.1  8      claims of discrimination (provided, however, that Employee releases his or her right to secure any damages  for alleged discriminatory treatment); any right to communicate directly with, cooperate with, or provide  information to, any federal, state or local government regulator; any right to file an unfair labor practice  charge under the National Labor Relations Act (“NLRA”); Employee’s vested rights under any retirement  or welfare benefit plan of the Company; Employee’s rights in his or her capacity as an equityholder of the  Company; or any other rights that may not be waived by an employee under applicable law.    3. Unknown Claims. Employee acknowledges that Employee has been advised of and is  familiar with the provisions of California Civil Code section 1542, which provides as follows:  “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE  CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR  AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR  HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH  THE DEBTOR.”  Employee, being aware of said Code section, hereby expressly waives any rights he or she may  have thereunder, as well as under any other statutes or common law principles of similar effect.  4. Representations.  Employee represents and warrants that there has been no assignment  or other transfer of any interest in any Claim which he or she may have against Releasees, or any of them,  and Employee agrees to indemnify and hold Releasees, and each of them, harmless from any liability,  Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as  the result of any such assignment or transfer or any rights or Claims under any such assignment or  transfer.  It is the intention of the parties that this indemnity does not require payment as a condition  precedent to recovery by the Releasees against Employee under this indemnity.  Employee agrees that if he  or she hereafter commences any suit arising out of, based upon, or relating to any of the Claims released  hereunder or in any manner asserts against Releasees, or any of them, any of the Claims released hereunder,  then Employee agrees to pay to Releasees, and each of them, in addition to any other damages caused to  Releasees thereby, all attorneys’ fees incurred by Releasees in defending or otherwise responding to said  suit or Claim.    5. No Actions.  Employee represents and warrants to the Company that Employee has no  pending actions, Claims or charges of any kind.  Employee agrees that if Employee hereafter commences,  joins in, or in any manner seeks relief through any suit arising out of, based upon, or relating to any of the  Claims released hereunder or in any manner asserts against the Releasees any of the Claims released  hereunder, then Employee will pay to the Releasees against whom such Claim(s) is asserted, in addition to  any other damages caused thereby, all attorneys’ fees incurred by such Releasees in defending or otherwise  responding to said suit or Claim; provided, however, that Employee shall not be obligated to pay the  Releasees’ attorneys’ fees to the extent such fees are attributable to Employee’s right to file a charge with  the EEOC; however, Employee hereby waives any right to any damages or individual relief resulting from  any such charge.  6. Exceptions.  Notwithstanding anything in this Release to the contrary, nothing  contained in this Release shall prohibit Employee (or Employee’s attorney) from (i) filing a charge with,  reporting possible violations of federal law or regulation to, participating in any investigation by, or  cooperating with the U.S. Securities and Exchange Commission (“SEC”), the Financial Industry  Regulatory Authority, the EEOC, the NLRB, the Occupational Safety and Health Administration, the U.S.  Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory  agency, self-regulatory authority or federal, state or local regulatory authority (collectively, “Government  Agencies”), or making other disclosures that are protected under the whistleblower provisions of applicable  

 

EXHIBIT 10.1  9      law or regulation, (ii) communicating directly with, cooperating with, or providing information (including  trade secrets) in confidence to any Government Agencies for the purpose of reporting or investigating a  suspected violation of law, or from providing such information to Employee’s attorney or in a sealed  complaint or other document filed in a lawsuit or other governmental proceeding, and/or (iii) receiving an  award for information provided to any Government Agency.  Pursuant to 18 USC Section 1833(b),  Employee will not be held criminally or civilly liable under any federal or state trade secret law for the  disclosure of a trade secret that is made: (x) in confidence to a federal, state, or local government official,  either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a  suspected violation of law; or (y) in a complaint or other document filed in a lawsuit or other proceeding,  if such filing is made under seal. Further, nothing in this Release is intended to or shall preclude Employee  from providing truthful testimony in response to a valid subpoena, court order, regulatory request or other  judicial, administrative or legal process or otherwise as required by law.  If Employee is required to provide  testimony, then unless otherwise directed or requested by a Governmental Agency or law enforcement,  Employee shall notify the Company in writing as promptly as practicable after receiving any such request  of the anticipated testimony and at least ten (10) days prior to providing such testimony (or, if such notice  is not possible under the circumstances, with as much prior notice as is possible) to afford the Company a  reasonable opportunity to challenge the subpoena, court order or similar legal process.   7. Miscellaneous.  (a) No Admission.  Employee understands and agrees that neither the payment of  money nor the execution of this Release shall constitute or be construed as an admission of any liability  whatsoever by the Releasees.  (b) Severability.  If any sentence, phrase, section, subsection or portion of this Release  is found to be illegal or unenforceable, such action shall not affect the validity or enforceability of the  remaining sentences, phrases, sections, subsections or portions of this Release, which shall remain fully  valid and enforceable.  (c) Headings.  The headings in this Release are provided solely for convenience, and  are not intended to be part of, nor to affect or alter the interpretation or meaning of, this Release.  (d) Construction of Agreement.  Employee has been represented by, or had the  opportunity to be represented by, counsel in connection with the negotiation and execution of this Release.   Any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not  be applied in the construction or interpretation of this Release.  (e) Entire Agreement/Integration. This Release, together with the Agreement and the  Restrictive Covenant Agreement, which is attached to the Agreement as an exhibit, constitutes the entire  agreement between Employee and the Company concerning the subject matter hereof.  No covenants,  agreements, representations, or warranties of any kind, other than those set forth herein, have been made to  any party hereto with respect to this Release.  All prior discussions and negotiations have been and are  merged and integrated into, and are superseded by, this Release.  No amendments to this Release will be  valid unless written and signed by Employee and an authorized representative of the Company.    Sign only on or within seven (7) days after January 8, 2021, which you acknowledge is that date that  you received this Release.   

 

EXHIBIT 10.1  10                    EMPLOYEE        Date: January 15, 2021    /s/ Neil Parikh       Neil ParikhEX-4.2

 Exhibit 4.2 

Confidential 
 DATED
3 OCTOBER 2016 
  
  

LumiraDx Limited 
 WARRANT
INSTRUMENT IN RESPECT OF WARRANTS TO SUBSCRIBE FOR A 
 ORDINARY SHARES IN LUMIRADX LIMITED 

NORTON ROSE FULBRIGHT 

 Contents 
  

							
	Clause	  	Page	 
			
	 1
	 	Definitions and interpretation	  	 	2	 
			
	 2
	 	Subscription Rights	  	 	6	 
			
	 3
	 	Exercising Subscription Rights	  	 	7	 
			
	 4
	 	Issue of Shares upon Exercise of Subscription Rights	  	 	8	 
			
	 5
	 	Restrictions and Obligations of the Company	  	 	9	 
			
	 6
	 	Modification of Rights	  	 	10	 
			
	 7
	 	Liquidation	  	 	10	 
			
	 8
	 	Certificates	  	 	11	 
			
	 9
	 	Meetings of Warrantholders	  	 	12	 
			
	 10
	 	Notices	  	 	12	 
			
	 11
	 	Third Party	  	 	13	 
			
	 12
	 	Governing Law	  	 	13	 
			
	 13
	 	Enforcement	  	 	13	 
		
	 Schedule 1 Form of Certificate
	  	 	15	 
		
	 Schedule 2 The Register and Transfers
	  	 	17	 
		
	 Schedule 3 Adjustments to Warrant Shares and Subscription Price
	  	 	19	 
		
	 Schedule 4 Provisions as to Meetings and Resolutions of Warrantholders
	  	 	20	 

 THIS WARRANT INSTRUMENT is executed on 3 October 2016 by LumiraDx Limited (company number
314391) a company incorporated in the Cayman Islands, whose registered office is at Estera Trust (Cayman) Limited, PO Box 1350, Clifton House, 75 Fort Street, Grand Cayman KY1-1108, Cayman Islands (the
Company) 
 WHEREAS 
  

	(A)	 The Company has, by resolution of its directors, agreed lo issue warrants lo subscribe for shares in the share
capital of the Company on the terms set out in this Warrant Instrument. 

  

	(B)	 All the registered holder(s) of shares in the Company have irrevocably waived all pre-emption rights conferred on them (whether by the CA 2006, the Articles or otherwise) in relation to the issue of Warrants (defined below) and shares in the Company pursuant to this Warrant Instrument.

  

	(C)	 The Company has accordingly executed this Warrant Instrument as a deed poll in favour of the
Warrantholders (defined below). 

 BY THIS WARRANT INSTRUMENT THE COMPANY DECLARES AND COVENANTS as follows: 

 

	1	 Definitions and interpretation 

 

	1.1	 In this Warrant Instrument, the following words and expressions shall have the following meanings unless the
context otherwise requires: 

 A Ordinary Shareholders holders of the A Ordinary Shares 

A Ordinary Shares means A ordinary shares of US $0.001 each in the capital of the Company (and, if there is a sub-division, consolidation or re-classification of those shares, any shares resulting from such sub-division, consolidation or re-classification) 
 Adjustment Event means any: 

 

	 	(i)	 sub-division, reclassification or consolidation of or in respect of the
Equity Shares; 

  

	 	(ii)	 allotment or issue of Equity Shares by way of capitalisation of profits or reserves (including share premium
account and any capital redemption reserve fund), scrip dividend or distribution in specie or bonus issue; and 

  

	 	(iii)	 cancellation or purchase by the Company of Equity Shares or any reduction or repayment of share capital or
reserve. 

  
 2 

 Admission or Admitted to Listing means: 

 

	 	(a)	 in the case of the A Ordinary Shares being admitted to trading on London Stock Exchange’s market for
listed securities: (i) the admission to the Official List of the UK Listing Authority becoming effective in accordance with the Listing Rules; and (ii) the admission to trading on the London Stock Exchange’s market for listed
securities becoming effective in accordance with the Admission and Disclosure Standards of the London Stock Exchange; or 

  

	 	(b)	 in the case of the A Ordinary Shares being approved for listing, subject only to notice of issuance, on any
U.S. National Securities Exchange; or 

  

	 	(c)	 in the case of the A Ordinary Shares being approved for listing on: (i) any other Recognised Investment
Exchange and their respective share dealing markets: (ii) any recognised overseas investment exchange (as defined by section 292, Financial Services and Markets Act 2000); or (iii) any investment exchange included in the Financial Conduct
Authority’s list of designated investment exchanges 

 Articles means the articles of association of the
Company from time to time 
 Asset Sale means the sale, lease, transfer or other disposition, in a single transaction or series of
related transactions, by the Company or any subsidiary, of all or substantially all the assets of the Company and its subsidiaries taken as a whole, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned
subsidiary of the Company 
 Auditors means the auditors of the Company from time to time 

Board means the board of directors of the Company from time to time 

Business Day means any day on which banks are generally open for business in London and the United States (excluding Saturdays, Sundays
and public holidays) 
 CA 2006 means the Companies Act 2006 

Certificate means a certificate evidencing the Warrantholder’s entitlement to Warrants in the form, or substantially in the form,
set out in Schedule 1 
 Company’s Account means the Company’s sterling bank account with the following details: 

 

					
	Bank:	 	HSBC Bank PLC	 	
			
	Account Number:	 	74861102	 	
			
	Sort Code:	 	400515	 	
			
	IBAN:	 	GB64MIDL40051574861102	 	

  
 3 

 Directors means the board of directors of the Company from time to time 

Equity Shares means shares in the capital of the Company which are “equity securities” as defined in section 560 of the
CA 2006 
 Event means an Asset Sale or Offer 

Exercise Date means the date on which a Warrantholder gives notice, in accordance with clause 3, of its intention to exercise any of its
Subscription Rights from time to time 
 Fair Market Value means, as of any particular date: (a) the volume weighted average of
the closing sales price of the A Ordinary Shares for such day on the Trading Market or (b) if there have been no sales of the A Ordinary Shares on the Trading Market on any such day, the average of the highest bid and lowest asked prices
for the A Ordinary Shares on such Trading Market at the end of such day; in each case, averaged over twenty (20) consecutive Business Days ending on the Business Day immediately prior to the day as of which Fair Market Value is being
determined; provided, that if the A Ordinary Shares are listed on any Trading Market, the term “Business Day” as used in this sentence means Business Days on which such exchange Is open for trading; and provided, further, that, in the
context of a Net Exercise in connection with an Event pursuant to clause 5.3, “Fair Market Value” shall mean the fair value of one A Ordinary Share as determined in good faith by the Company’s Board of Directors based on the Event
giving rise to the Net Exercise 
 Notice of Subscription has the meaning ascribed to it in clause 3.1 

Note, Warrant and Stock Purchase Agreement means the agreement entered into by the Company and each of USB Focus Fund LumiraDx 1-A, LLC and USB Focus Fund LumiraDx 1- B, LLC on or around the date hereof 

Offer an Offer by a Person to acquire the entire issued A Ordinary Share capital of the Company 

Offer Price means the price per A Ordinary Share paid to the A Ordinary Shareholders of the Company by a Person pursuant to an Offer

 Permitted Transferee has the meaning ascribed to it in clause 5.5 

Person means an individual, corporation, partnership, limited liability company, joint venture, trust, or unincorporated organization,
or a government or any agency or political subdivision thereof 
 Recognised Investment Exchange shall have the meaning ascribed to it
in section 285(1)(a) of the Financial Services and Markets Act 2000 

  
 4 

 Register means the register of persons for the time being entitled to the benefit of
the Warrants required to be maintained pursuant to this Warrant Instrument 
 Special Resolution has the meaning ascribed to it in
paragraph 18 of Schedule 4 
 Subscription Price means US$611.628 per Warrant Share 

Subscription Rights means the subscription rights of the Warrantholder as defined in clause 2.1 

Trading Market means the London Stock Exchange’s market for listed securities, any U.S. National Securities Exchange or any form of
over-the-counter quotation platform, as applicable, if such exchange or market is the principal market on which the A Ordinary Shares are then traded 

U.S. National Securities Exchange means a “national securities exchange” as defined in Section 6 of the Securities
Exchange Act of 1934, as amended 
 Warrantholder means in relation to a Warrant, the person who appears in the Register as the holder
of the Warrant 
 Warrants means the warrants of the Company constituted in this Warrant Instrument and all rights conferred by it
(including Subscription Rights) 
 Warrant Shares means up to 13,067 new A Ordinary Shares issuable upon the exercise of the
Subscription Rights 
  

	1.2	 In this Warrant Instrument, unless the context requires otherwise: 

 

	 	(a)	 Any expression or word used in this Warrant Instrument which is not defined in it but which has been defined in
the Articles shall have the meaning given to it in the Articles unless the context requires otherwise; 

  

	 	(b)	 headings to clauses and paragraphs are for information only and shall not form part of the operative provisions
of this Warrant Instrument and shall be ignored in its construction; 

  

	 	(c)	 references to recitals, clauses or schedules are to recitals to, clauses of and schedules to this Warrant
Instrument. The recitals and schedules form part of the operative provisions of this Warrant Instrument and references to this Warrant Instrument shall, unless the context otherwise requires, include references to the recitals and schedules;

  

	 	(d)	 references to statutes or statutory provisions include references to any orders or regulations made under them
and any references to any statute, provision, order or regulation include references to that statute, provision, order or regulation as amended, 

  
 5 

	 	
modified, re-enacted or replaced from time to time whether before or after the date of this Warrant Instrument (subject as otherwise expressly provided in
this Warrant Instrument) and to any previous statute, statutory provision, order or regulation amended, modified, re-enacted or replaced by such statute, provisions, order or regulation provided that nothing
in this clause shall have the effect of increasing the liability of any party; 

  

	 	(e)	 the terms subsidiary and holding company have the meanings ascribed by section 1159 CA 2006 and include parent
and subsidiary undertakings as defined in section 1162 CA 2006; 

  

	 	(f)	 In this Warrant Instrument, the words other, includes, including and in particular do not limit
the generality of any preceding words and any words which follow them shall not be construed as being limited in scope to the same class as the preceding words where a wider construction is possible. 

 

	2	 Subscription Rights 

 

	2.1	 Subscription Rights 

Each Warrant confers the right (but not the obligation) (Subscription Rights) on the Warrantholder to subscribe in cash at the
Subscription Price for such number of Warrant Shares in respect of which it is recorded in the Register as the holder of on the terms set out in this Warrant Instrument. 

Entitlement to all rights attaching to the Warrants shall be evidenced by the issue to a Warrantholder of a Certificate. One Certificate shall
be issued to each Warrantholder for all of the Warrants registered in its name. The Company shall issue a copy of this Warrant Instrument with each Certificate. 
  

	2.2	 Adjustment Event 

If an Adjustment Event occurs, the number and nominal value of Warrant Shares which the Warrantholders are entitled to subscribe and (as
appropriate) the Subscription Price payable in respect of such subscription shall be adjusted in accordance with the provisions set out in Schedule 3. If requested by the Warrantholder in writing, the Company will use its commercially reasonable
efforts to cause its Auditors to certify the appropriate adjustment in accordance with Schedule 3. 

  
 6 

	3	 Exercising Subscription Rights 

 

	3.1	 Timing 

Each of the Warrantholders may at any time, and from time to time, exercise their Subscription Rights in whole or part by delivering to the
Company a notice substantially in the form contained in the Certificate (Notice of Subscription) together with: 
  

	 	(a)	 the Certificate for the Warrants in respect of which Subscription Rights are being exercised; and

  

	 	(b)	 a payment by telegraphic transfer to the Company’s Account (or such other mode of payment as the Company
and the Warrantholder shall agree) of the aggregate Subscription Price in respect of the Subscription Rights which are being exercised. 

  

	3.2	 On any exercise of the Warrantholder’s Subscription Rights, in lieu of payment of the aggregate
Subscription Price in the manner specified in clause 3.1(b) above, but otherwise in accordance with the requirements of this clause 3.2, the Warrantholder may elect to receive, and the Company shall issue to the Warrantholder such number of Warrant
Shares as are computed using the following formula (a Net Exercise): 

 X = Y *
(A-B) / A 
 where 

X = the number of Warrant Shares to be issued to the Warrantholder; 

Y = the number of Warrant Shares with respect to which this Warrant is being exercised (inclusive of the Warrant Shares sold by the Company (on
behalf of the relevant Warrantholder) in payment of the aggregate Subscription Price or, following a Net Exercise contemplated by clause 5.3); 

A= the Fair Market Value of one A Ordinary Share as of the exercise date; and B = the Subscription Price. 

To give effect to the above provisions, the Warrantholder authorises the Company to sell such number of Warrant Shares as it indicates to fund
in part the balance of the Subscription Price for the Warrant Shares the Warrantholder wishes to subscribe for. The provisions of this clause 3.2 shall only apply after Admission or as contemplated by clause 5.3. 

  
 7 

	3.3	 For the avoidance of doubt, where part only of a Warrantholder’s total Subscription Rights are exercised,
the Company shall update the Register to record the remaining Subscription Rights in respect of such Warrantholder following the partial exercise of its Subscription Rights and shall issue to such Warrantholder an updated certificate confirming the
remaining Subscription Rights in respect of which ii is recorded in the Register as the holder on the terms set out in this Warrant Instrument. 

  

	3.4	 Irrevocable Election 

Delivery of the items specified in clause 3.1 to the Company shall, other than with the Company’s written consent, be an irrevocable
election by the relevant Warrantholder to exercise the relevant Subscription Rights. 
  

	3.5	 Lapse 

All Subscription Rights not exercised shall lapse on the date falling ten years from the date of this Warrant Instrument (the Termination
Date). 
  

	4	 Issue of Shares upon Exercise of Subscription Rights 

 

	4.1	 Allotment and Issue 

Following receipt of a Notice of Subscription, the Company shall 
  

	 	(a)	 within thirty (30) Business Days after the Exercise Date, resolve to allot and issue to the
person(s) identified in the relevant Notice of Subscription (Allottee(s)) the Warrant Shares specified in the Notice of Subscription and to enter the Allottee(s)’ name in the register of members of the Company as the holder of the
Warrant Shares issued to such Allottee(s); and 

  

	 	(b)	 within thirty (30) Business Days of the allotment and issue of the Warrant Shares pursuant to this clause
4 (Warrant Share Delivery Date), at the Company’s cost, send to the address stipulated in the Notice of Subscription share certificate(s) in respect of the Warrant Shares issued and (in the event of a partial exercise by any
Warrantholder) a balancing Certificate in respect of those Subscription Rights which remain unexercised. 

  

	4.2	 Rights attaching to Warrant Shares 

The Warrant Shares allotted pursuant to the exercise of the Subscription Rights shall: 

 

	 	(a)	 be allotted and issued fully paid; and 

 

	 	(b)	 rank pari passu with the fully paid A Ordinary Shares then in issue and have the rights set out in the Articles
relating to the A Ordinary Shares. 

  
 8 

	 	(c)	 subject to the Articles, be entitled to receive any dividend or other distribution which has previously been
announced or declared provided that the record date by which the holder of Warrant Shares must be registered to participate in such dividend or other distribution is after the date on which the Warrant Shares are allotted and issued.

  

	4.3	 Rounding 

If the number of Warrant Shares falling to be allotted to a Warrantholder (or at its direction) on an exercise of Subscription Rights would
otherwise require a fraction of a Warrant Share to be allotted, the number of Warrant Shares to be so allotted will be rounded down to the nearest whole number of Warrant Shares. 

 

	5	 Restrictions and Obligations of the Company 

 

	5.1	 Undertakings 

For so long as any Subscription Rights remain outstanding, the Company will comply with the undertakings in this clause 5. 

 

	5.2	 Covenants 

Subject to clause 5.3, as long as any Warrants remain outstanding, the Company covenants to the Warrantholders as follows: 

 

	 	(a)	 it will procure that at all times there are available for issue sufficient A Ordinary Shares free from pre-emptive rights to satisfy in full the exercise of Subscription Rights in respect of all outstanding Warrants (taking into account any other obligations of the Company to issue any shares in the Company); and

  

	 	(b)	 unless approved by the shareholders of the Company by written resolution or at a general meeting on or prior to
the date hereof or unless authorised by the Board at a duly convened meeting of the Board held on or prior to the date hereof, it will notify the Warrantholder in writing of any proposed issue of securities to the holders of A Ordinary Shares as a
class by way of rights at least 10 Business Days prior to the proposed date of such issue. 

  

	5.3	 Events and Adjustment Events 

 

	 	(a)	 The Company will notify each Warrantholder in writing within three Business Days of the publication of any
regulatory news service announcement in respect of a proposed Event specifying the proposed date and nature of such Event, provided that nothing in this clause 5.3(a) shall require the Company to provide any information relating to the proposed
Event which has not already been made public pursuant to a regulatory news service announcement; 

  
 9 

	 	(b)	 In respect of any Offer, the Company shall procure that (i) appropriate provision is made in connection
with the Offer such that the Warrantholder shall, following the announcement of the Offer, be entitled, upon exercise of these Warrants, to receive the number of shares or other securities of the Company, or other successor entity, or property
(including cash) as to which the Warrantholder would have been entitled if the Warrantholder had exercised its rights pursuant to this Warrant immediately prior thereto and was able to participate in the Offer, or (ii) appropriate provision is
made in connection with the Offer such that, upon the consummation thereof, and without any exercise of this Warrant by the Warrantholder or other action, the Warrantholder shall be entitled to receive the number of shares or other securities of the
Company, or other successor entity, or property (including cash) as to which the Warrantholder would have been entitled if the Warrantholder had exercised its rights pursuant to the Warrants immediately prior thereto on a Net Exercise basis as set
forth in clause 3.2. 

  

	5.4	 Shareholders, Board and Management Meetings 

Each of the Warrantholders shall have the right to: 
  

	 	(a)	 receive notice of all shareholders meetings of the Company and class meetings of the holders of A Ordinary
Shares but shall not be entitled to attend, speak or vote at those meetings in its capacity as a Warrantholder; and 

  

	 	(b)	 receive (at the same time as the relevant shareholders) a copy of any proposed written resolution of the
shareholders or any proposed written class consent of the holders of A Ordinary Shares but shall not be entitled to vote on those resolutions in its capacity as a Warrantholder. 

 

	5.5	 Transfer of Warrants 

Notwithstanding the transfer provisions set out in Schedule 2, the Warrants may only be transferable, in whole or in part by the Warrantholder
to any other person or entity permitted in accordance with Section 1.09 of the Note, Warrant and Stock Purchase Agreement (together the Permitted Transferees). 
  

	6	 Modification of Rights 

This Warrant Instrument may be modified only with the prior sanction of a Special Resolution in accordance with the provisions of Schedule 4.

  

	7	 Liquidation 

  

	7.1	 Liquidation and Dissolutions 

If an order is made or an effective resolution is passed for the winding-up or dissolution of the
Company or if any other dissolution of the Company by operation of law is to be effected then the provisions of clause 7.2 or 7.3 shall apply. 

  
 10 

	7.2	 Sanctioned Agreement 

If the winding-up or dissolution is for the purpose of a reorganisation or amalgamation pursuant to a
scheme of arrangement sanctioned by a special resolution of the Company, the terms of the scheme of arrangement will be binding on the Warrantholder. 
  

	7.3	 Non Sanctioned Agreement 

If clause 7.2 does not apply, the Company shall immediately notify the Warrantholders, in writing, that such an order has been made or
resolution has been passed or other dissolution is to be effected. The Warrantholders shall be entitled at any time within three months after the date such notice is given to elect by notice in writing to the Company to be treated as if they
had, immediately before the date of the making of the order or passing of the resolution or other dissolution, exercised the Subscription Rights and they shall be entitled to receive out of the assets which would otherwise be available
in the liquidation to the holders of A Ordinary Shares, such a sum, if any, as they would have received had they been the holders of and paid for the Warrant Shares to which they would have become entitled by virtue of such exercise, after deducting
from such sum the amount which would have been payable by them in respect of the Warrant Shares if they had exercised the Subscription Rights. Nothing contained in this paragraph shall have the effect of requiring the Warrantholders to make any
actual payment to the Company. If no such notice is given by the Warrantholders within the three month period specified above, the Subscription Rights shall lapse without claim if an order is made or an effective resolution is passed for the winding-up or the dissolution of the Company. 
  

	8	 Certificates 

  

	8.1	 Issues of Certificates 

Within five Business Days of entering the name of a Warrantholder in the Register of the Company, the Company shall issue to the Warrantholder
a Certificate in respect of the Subscription Rights in respect of which it is recorded in the Register as the holder. 

  
 11 

	8.2	 Lost Certificates, etc 

If a Certificate is mutilated, defaced, lost, stolen or destroyed the Company will replace it provided that: 

 

	 	(a)	 the Warrantholder seeking the replacement provides the Company with such evidence and indemnity in
respect of the mutilation, defacement, loss, theft or destruction as the Company may reasonably require; 

  

	 	(b)	 the Warrantholder seeking the replacement pays the Company’s reasonable costs in connection with the issue
of the replacement; 

  

	 	(c)	 mutilated or defaced Certificates in respect of which replacements are being sought are surrendered

  

	9	 Meetings of Warrantholders 

The provisions of Schedule 4 shall apply in relation to meetings of Warrantholders. 

 

	10	 Notices 

  

	10.1	 Mode of Service 

Subject to clause 10.2 any notice, demand or other communication given or made under or in connection with the matters contemplated by this
Warrant Instrument shall be in writing and shall be delivered personally or sent by fax or prepaid first class post: 
  

	 	(a)	 In the case of the Company to: 

 

			
	Name:	  	LumiraDx Limited
		
	Address:	  	3 More London Riverside, London SE1 2AQ, England
		
	Name:	  	General Counsel (c/o Ian Lopez/Nicholas Skill)

  

	 	(b)	 in the case of a Warrantholder to the address of the Warrantholder shown in the Register or, if no address is
shown in the Register, to its last known place of business or residence; 

  

	10.2	 Procedure if no known address 

If no address has been notified to the Company by a Warrantholder, any notice, demand or other communication given or made under or in
connection with the matters contemplated by this Warrant Instrument may be given to that Warrantholder by the Company by exhibiting it for ten Business Days at the registered office of the Company. 

  
 12 

	10.3	 Deemed Service 

Any notice, demand or other communication given or made under or in connection with the matters contemplated by this Warrant Instrument shall
be deemed to have been duly given or made as follows: 
  

	 	(a)	 if personally delivered, upon delivery at the address of the relevant party; 

 

	 	(b)	 if sent by first class post, ten Business Days after the date of posting; 

 

	 	(c)	 if clause 10.2 applies, at the expiry of the ten Business Day period referred to in that clause

 provided that if, in accordance with the above provision, any such notice, demand or other communication would otherwise
be deemed to be given or made after 5.30 pm such notice, demand or other communication shall be deemed to be given or made at 9.30 am on the next Business Day. 
  

	10.4	 Joint Registered Holders 

All notices and other communications with respect to Warrants standing in the names of joint registered holders shall be given to whichever of
such persons is named first in the Register and such notice so given shall be sufficient notice to all the registered holders of such Warrants. 
  

	10.5	 Successors 

Any person who becomes entitled to any Warrant (whether by operation of law, transfer or otherwise) shall be bound by every notice given in
respect of that Warrant before its name and address is entered on the Register. 
  

	11	 Third Party 

The parties to this Warrant Instrument expressly agree for the purposes of the Contracts (Rights of Third Parties) Act 1999 that they do not
intend any person other than a party to this Warrant Instrument or a Warrantholder to be able to enforce any term of this Warrant Instrument. 
  

	12	 Governing Law 

This Warrant Instrument and any non-contractual obligations arising out of or in connection with it are
governed by English law. 
  

	13	 Enforcement 

The courts of England have exclusive jurisdiction to settle any dispute arising out of or in connection with this Warrant Instrument (including
a dispute relating to the existence, validity or termination of this Warrant Instrument or any non-contractual obligation arising out of or in connection with this Warrant Instrument). 

  
 13 

 Schedule 1 Form of Certificate 

LUMIRADX LIMITED 

Registered in the Cayman Islands (No. [         ]) 

WARRANT CERTIFICATE 

Warrant Certificate Number [____] 
 This is to
certify that the person named below is a Warrantholder for the purpose of the warrant instrument issued by the Company                     on 2016
(Warrant Instrument) and has the right to subscribe in cash at the aggregate Subscription Price for that number of the Warrant Shares (as defined in the Warrant Instrument) specified below on the terms set out in the Warrant Instrument. 

Warrantholder 
 Name: 

Address: 
 Number of Warrant Shares represented by this
Certificate: [_________] 
 (Subject to adjustment in accordance with clause 2.2 of the Warrant Instrument) 

Total Subscription Price for Warrant Shares represented by this Certificate: [$______] 

Date of Issue: 
 Executed as a Deed
by:    ______________________ 
 LumiraDx Limited     ______________________ 

acting by a director in the presence of 
  

 
 Signature of witness 

Name _______________________________ 
 Address
_______________________________ 
 Notes: 
  

	 	(1)	 The Subscription Rights are transferable prior to exercise only in accordance with the provisions of the
Warrant Instrument. 

  

	 	(2)	 All transfers must be accompanied by this Warrant Certificate. 

  
 15 

 NOTICE OF SUBSCRIPTION 

(To be printed on the back of the Certificate) 

We hereby exercise [the Subscription Rights as set out below] pursuant to this certificate and confirm payment by [telegraphic transfer to the Company’s
account] [other method of payment agreed by the Company] of£[•] being the Subscription Price payable in respect of the aggregate Subscription Rights we are exercising. We acknowledge that the legal and beneficial title to
the relevant A Ordinary Shares are accepted subject to the Articles of Association of the Company. 
 We direct the Company pursuant to this exercise to
allot and issue the number of A Ordinary Shares to be issued pursuant to this exercise to the following proposed allottees. The aforesaid A Ordinary Shares are to be issued in connection with the exercise of Warrants originally purchased by way of
private placement transaction conditionally approved by LumiraDx Limited on [ ] 2016. Any proposed allottee must be a person or entity permitted in accordance with Section 1.09 of the Note, Warrant and Stock Purchase Agreement: 

 

													
	 	  	 [_________]

Number of A
Ordinary
Shares
	 	  	 Name of

Allottee
	 	  	 Proposed Address of Proposed

Allottee
	 
				
	 1.
	  				  				  			
				
	 2.
	  				  				  			
				
	 3.
	  				  				  			
				
	 4.
	  				  				  			

 We hereby instruct you to sell [_________] Warrant Shares to fund the Subscription Price for the balance of our entitlement in
accordance with clause 3.2. 
 Share certificates should be sent to [include details] 

Signed                _____________________________
                        Print                
Name 
 ________________________________ Address    ________________________________________ 

______________________________ [*Details of all rights should be inserted as shown.] 
  

	[’*	 Number of shares over which rights are to be exercised.] 

  
 16 

 Schedule 2 

The Register and Transfers 
  

	1	 Register 

  

	1.1	 An accurate register of entitlement to the Warrants (the Register) will be kept by the Company at its
registered office in which the Company shall enter: 

  

	 	(a)	 the names and addresses of the persons for the time being entitled to be registered as the holders of the
Warrants: 

  

	 	(b)	 the number of Warrants held by every registered holder; and 

 

	 	(c)	 the date on which the name of every registered holder is entered in the Register in respect of the Warrants in
his name. 

  

	1.2	 Any change in the name or address of any Warrantholder shall be notified as soon as reasonably practicable
following such change to the Company which shall cause the Register to be amended accordingly. Any Warrantholder and any person authorised by any Warrantholder may at all reasonable times during office hours inspect the Register and take copies of
or extracts from it or any part of it. 

  

	1.3	 The Company may treat the registered Warrantholder as the absolute owner of a Warrant and accordingly shall
not, except as ordered by a court of competent jurisdiction or as required by law, be bound to recognise any equitable or other claim to or interest in a Warrant on the part of any other person, whether or not it shall have express or other notice
of such a claim. 

  

	1.4	 Every Warrantholder will be recognised by the Company as entitled to its Warrants free from any equity, set-off or cross-claim on the part of the Company against the original or any intermediate holder of the Warrants. 

  

	2	 Transfers 

  

	2.1	 The Warrants may only be transferable in whole or in part by a Warrantholder to any other person or entity
permitted in accordance with Section 1.09 of the Note, Warrant and Stock Purchase Agreement. 

  

	2.2	 Every transfer of a Warrant shall be made by an instrument of transfer in the usual or common form or in any
other form which may be approved by the Directors. 

  
 17 

	2.3	 The instrument of transfer of a Warrant shall be executed by or on behalf of the transferor but need not be
executed by or on behalf of the transferee. The transferor shall be deemed to remain the holder of the Warrant until the name of the transferee is entered in the Register in respect of the Warrant being transferred. 

 

	2.4	 No fee shall be charged for any registration of a transfer of a Warrant or for the registration of any other
documents which in the opinion of the Directors require registration. 

  

	2.5	 The registration of a transfer shall be conclusive evidence of the approval by the Directors of such a
transfer. 

  

	3	 Stock Exchange Dealings 

 

	3.1	 Provided that at the time of issue of Warrant Shares pursuant to the exercise of the Warrants, the A Ordinary
Shares (or any of them) are quoted on the Official List of the United Kingdom Listing Authority, admitted to trading on the Alternative Investment Market operated by The London Stock Exchange pie, and/or permission or approval has been granted for
dealings therein or listing on any U.S. National Securities Exchange or any Recognised Investment Exchange in any part of the world, the Company will apply to such exchange or body for permission to deal in, approval to list or for quotation of and
Admission of such Warrant Shares (as the case may be) and shall use its commercially reasonable efforts to secure such permission or quotation as soon as reasonably practicable after the issue of such Warrant Shares. 

  
 18 

 Schedule 3 

Adjustments to Warrant Shares and Subscription Price 

If there is an Adjustment Event whilst the Warrants are outstanding, the number and nominal value of Warrant Shares to be, or capable of
being, subscribed on any subsequent exercise of the Subscription Rights and the Subscription Price will be adjusted in such manner as the Auditors (acting on the joint instructions of the Warrantholders and the Company, as experts and not as
arbitrators) shall certify to be necessary in order that, after such adjustment: 
  

	 	(a)	 the total number of Warrant Shares to be, or capable of being, subscribed on any subsequent exercise of the
Subscription Rights conferred by the Warrants: 

  

	 	(i)	 will carry as nearly as possible (and in any event not less than) the same proportion (expressed as a
percentage of the total number of votes exercisable in respect of all the Equity Shares) of the votes available to be cast at a general meeting of the Company; and 

 

	 	(ii)	 will carry the same entitlement (expressed as a percentage of the total entitlement conferred by all the Equity
Shares) to participate in the profits and assets of the Company; 

 as would the total number of Warrant Shares which could
have been subscribed pursuant to the Subscription Rights conferred by the Warrants had there been no such adjustment and no such event giving rise to such adjustment; and 
  

	 	(b)	 the aggregate Subscription Price payable in order to subscribe for all the Warrant Shares will be as nearly as
possible the same as it was prior to such adjustment. 

  

	2	 In calculating the aggregate entitlement to additional Subscription Rights under paragraph 1, any entitlement
to a fraction of a Warrant Share shall be rounded down to the nearest whole Warrant Share. 

  

	3	 The Company will send the Warrantholders notice of any adjustments to the Subscription Rights as soon as
reasonably practicable after the relevant resolution of the Board giving effect to or sanctioning the Adjustment Event together with a replacement Warrant Certificate evidencing each Warrantholder’s adjusted Subscription Rights.

  
 19 

 Schedule 4 

Provisions as to Meetings and Resolutions of Warrantholders 
  

	1	 Calling of Meetings 

The Company may at any time, and shall upon a request in writing signed by Warrantholders holding Warrants conferring not less than 10% of the
Subscription Rights then outstanding, convene a meeting of Warrantholders in default of which such Warrantholders shall convene such meeting themselves. Every such meeting shall be held at such reasonably convenient and appropriate place in the
United Kingdom as the Directors may approve. 
  

	2	 Notice of Meetings 

At least 21 clear days’ notice of the meeting shall be given to Warrantholders of any meeting of Warrantholders. Any meeting of
Warrantholders may be called by shorter notice if it is so agreed by Warrantholders holding Warrants conferring not less than 90% of the Subscription Rights then outstanding. The notice shall specify the date, time and place of the meeting and the
terms of the resolutions to be proposed. The accidental omission to give notice to, or the non-receipt of any such notice by, any of the Warrantholders shall not invalidate the proceedings at any meeting. 

 

	3	 Chairman 

A person (who may, but need not be, a Warrantholder) nominated in writing by the Company shall be entitled to take the chair at every such
meeting but if no such nomination is made, or if at any meeting the person nominated shall not be present within 15 minutes after the time appointed for the holding of such meeting, the Warrantholders present shall choose one of their number to be
chairman. 
  

	4	 Quorum at Meetings 

At any such meeting other than one at which a Special Resolution is proposed to be passed, two or more persons holding Warrants and/or being
proxies and being or representing in aggregate Warrantholders registered as the holders of Warrants conferring not less than 10% of the Subscription Rights then outstanding shall form a quorum for the transaction of business. The quorum at any such
meeting for the passing of a Special Resolution shall, subject to the remaining provisions of this paragraph 4, be two or more persons holding Warrants and/or being proxies and being or representing in the aggregate Warrantholders registered
as the holders of Warrants conferring not less than 50% of the Subscription Rights. No business other than the choosing of a chairman shall be transacted at any meeting unless the requisite quorum be present at the commencement of business. Whenever
there is only one holder of Warrants, a quorum at any meeting of Warrantholders shall, for all purposes, be that Warrantholder or any proxy for that Warrantholder. 

  
 20 

	5	 Absence of Quorum 

If, within half an hour after the time appointed for any meeting a quorum is not present, the meeting shall, if convened upon the requisition
of Warrantholders, be dissolved. In any other case it shall stand adjourned for such period, not being less than 14 days nor more than 28 days, and to such time and place, as may be appointed by the chairman. At such adjourned meeting one person
present in person holding Warrants or being a proxy shall for all purposes form a quorum and shall have the power to pass any resolution (including a Special Resolution) and to decide upon all matters which could properly have been dealt with at the
meeting from which the adjournment took place had a quorum been present at such meeting. 
  

	6	 Adjournment of Meetings 

The chairman may with the consent of (and shall if directed by) any meeting adjourn the same from time to time and from place to place but no
business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the meeting from which the adjournment took place. 
  

	7	 Notice of Adjournment of Meetings 

At least five days’ notice of any meeting adjourned through want of a quorum shall be given to Warrantholders in the same manner as of an
original meeting, and such notice shall state the quorum required at such adjourned meeting. Subject as aforesaid, it shall not be necessary to give any notice of an adjourned meeting. 

 

	8	 Resolution on Show of Hands 

Every question submitted to a meeting shall be decided in the first instance by a show of hands and in case of equality of votes the
chairman shall both on a show of hands and on a poll have a casting vote in addition to the vote or votes (if any) to which the chairman may be entitled as a Warrantholder or as a proxy. 

 

	9	 Demand for Poll 

At any meeting, unless a poll is demanded by the chairman or by one or more Warrantholders (or by their proxies) being or representing in the
aggregate Warrantholders registered as the holders of Warrants conferring not less than 10% of the Subscription Rights then outstanding (before or on the declaration of the result of a show of hands), a declaration by the chairman that a resolution
has been carried or carried by a particular majority or lost or not carried by any particular majority shall be conclusive evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against such resolution.

  
 21 

	10	 Manner of taking Poll 

If at any meeting a poll is so demanded, it shall be taken in such manner and, subject as hereinafter provided, either at once or after any
adjournment, as the chairman directs, and the result of such poll shall be deemed to be the resolution of the meeting at which the poll was demanded The demand for a poll shall not prevent the continuance of the meeting for the transaction of any
business other than the question on which the poll has been demanded. 
  

	11	 Time for taking Poll 

Any poll demanded at any meeting on the election of a chairman or on any question of adjournment shall be taken at the meeting without
adjournment. 
  

	12	 Persons Entitled to Attend, Speak and Vote 

The Company (through its representatives) and its legal and financial advisers shall be entitled to attend and speak at any meeting of
Warrantholders. Save as aforesaid, no person shall be entitled to attend or vote at any meeting of Warrantholders or to join with others in requesting the convening of such a meeting unless he is a Warrantholder, the duly appointed corporate
representative of a corporate Warrantholder, or a duly appointed proxy of a Warrantholder. 
  

	13	 Instrument Appointing a Proxy 

A Warrantholder shall be entitled to appoint a proxy to attend any meeting of the Warrantholders and to vote at such meeting on behalf of such
Warrantholder. Every instrument appointing a proxy must be in writing signed by the Warrantholder or (in the case of a corporation) by a duly authorised officer of the Warrantholder and shall be in such form as the Directors may approve (acting
reasonably). Such instrument of proxy shall unless the contrary is stated thereon be valid as well for an adjournment of the meeting as for the meeting to which ii relates and need not be witnessed. A person appointed to act as a proxy need not be a
Warrantholder. 
  

	14	 Deposit of Instrument Appointing a Proxy 

The instrument appointing a proxy and the power of attorney or other authority (if any) under which it is signed or a notarially certified or
office copy of such power of attorney shall be deposited at such place or places as the Company (or the Warrantholders in default of the Company convening the meeting) may in the notice of meeting direct or if no such place is specified then at the
registered office of the Company, not less than forty-eight hours before the time appointed for holding the meeting or adjourned meeting or the taking of a poll at which the 

  
 22 

 
person named in such instrument proposes to vote and in default the instrument of proxy shall not be treated as valid. A vote given in accordance with the terms of an instrument appointing a
proxy shall be valid notwithstanding the previous revocation of the instrument of proxy or of the authority under which the instrument of proxy is given or transfer of the Warrants in respect of which it is given unless previous intimation in
writing of such revocation or transfer shall have been received at the registered office of the Company. No instrument appointing a proxy shall be valid after the expiration of twelve months from the date named in it as the date of its execution.

  

	15	 Votes 

Subject as provided in paragraph 8 of this schedule, at any meeting: 
  

	 	(a)	 on a show of hands each Warrantholder who is present in person (or in the case of a corporation by a duly
authorised representative) and each person who is a proxy shall have one vote; and 

  

	 	(b)	 on a poll each Warrantholder who is present in person or by proxy as aforesaid shall have a number of votes
equal to the proportion (expressed as a percentage figure rounded up or, as appropriate, down to the nearest one tenth of one%) of the outstanding Subscription Rights represented by Warrants held by him. Any person entitled to more than one vote
need not use all his votes or cast all the votes to which he is entitled in the same way. 

  

	16	 Powers of Meetings of Warrantholders 

A meeting of Warrantholders shall in addition to all other powers (but without prejudice to any powers conferred on other persons by this
Instrument) have the following powers exercisable by a Special Resolution, namely: 
  

	 	(a)	 power to sanction any compromise or arrangement proposed to be made between the Company and the Warrantholders
or any of them; 

  

	 	(b)	 power to sanction any proposal by the Company for the modification, abrogation, variation or compromise of, or
arrangement in respect of, the rights of the Warrantholders against the Company whether such rights shall arise under this instrument or otherwise; 

  

	 	(c)	 power to sanction any proposal by the Company for the exchange or substitution for the Warrants of, or the
conversion of the Warrants into, shares, stock, bonds, debentures, debenture stock or other obligations or securities of the Company, or any other body corporate formed or to be formed; 

  
 23 

	 	(d)	 power to assent to any modification of the provisions contained in this Instrument which shall be proposed by
the Company; 

  

	 	(e)	 power to authorise any person to concur in and execute and do all such documents, acts and things as may be
necessary to carry out and give effect to a Special Resolution; 

  

	 	(f)	 power to discharge or exonerate any person from any liability in respect of any act or omission for which such
person may have become responsible under this Instrument; 

  

	 	(g)	 power to give any authority, direction or sanction which under the provisions of this Instrument is required to
be given by a Special Resolution; and 

  

	 	(h)	 power to appoint any persons (whether Warrantholders or not) as a committee or committees to represent the
interest of the Warrantholders and to confer upon such committee any powers or discretions which the Warrantholders could themselves exercise by a Special Resolution. 

 

	17	 A Special Resolution binding on all Warrantholders 

A Special Resolution shall be binding upon all the Warrantholders, whether present or not present at such meeting, and each of the
Warrantholders shall be bound to give effect thereto accordingly. The passing of any such resolution shall be conclusive evidence that the circumstances of such resolution justified the passing thereof. 

 

	18	 Definition of a Special Resolution 

The expression Special Resolution when used in this Instrument means a resolution passed at a meeting of the Warrantholders duly
convened and held and carried by a majority consisting of no less than 75% of the votes cast upon a show of hands or, if a poll is duly demanded, by a majority consisting of not less than 75% of the votes cast on a poll. 

 

	19	 Minutes of Meetings 

Minutes of all resolutions and proceedings at every meeting shall be made and duly entered in books to be from time to time provided for that
purpose by the Company, and any such minutes, if the same are signed by the chairman of the meeting at which such resolutions were passed or proceedings transacted or by the chairman of the next succeeding meeting of the Warrantholder, shall be
conclusive evidence of the matters therein contained and, until the contrary is proved, every meeting in respect of the proceedings of which minutes have been made and signed as aforesaid shall be deemed to have been duly convened and held and all
resolutions passed or proceedings transacted thereafter to have been duly passed and transacted. 

  
 24 

	20	 Further Provisions 

Subject to all other provisions contained in this Instrument the Company may without the consent of the Warrantholders prescribe such further
regulations regarding the holding of meetings of Warrantholders and attendance and voting thereat as the Company may at its discretion determine. 
  

	21	 Written Resolution 

Anything which, under the terms of this Instrument, may be done by resolution passed at a meeting of the Warrantholders (including
specifically, but without limitation, the passing of a Special Resolution) may be done, without a meeting and without any previous notice being required, by resolution in writing signed by or on behalf of the Warrantholders holding not less than 75%
of the Warrant Shares. The signatures to any such resolution need not be on a single document provided each is on a document which accurately states the terms of the resolution. The date of the resolution shall be the date when the resolution is
signed by or on behalf of the last Warrantholder to sign. 

  
 25 

 Executed and delivered by the Company as a Deed on the date stated at the beginning of this Deed. 

 

					
	Date of Issue:	 		  	
			
	Executed as a Deed by	 		  	 /s/ Ron Zwanziger

			
	 LumiraDx Limited
  

acting by a director in the presence of
	 	            	  	
			
	 /s/ Carol A. Smith
	 		  	
			
	Signature of witness	 		  	
			
	Name Carol A. Smith                            	 		  	
			
	Notes:                                     
                	 		  	

  

  
 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]